ATYR
Price
$5.35
Change
+$0.21 (+4.09%)
Updated
Jun 5 closing price
Capitalization
474.39M
68 days until earnings call
NTLA
Price
$7.58
Change
-$0.09 (-1.17%)
Updated
Jun 5 closing price
Capitalization
784.13M
55 days until earnings call
Interact to see
Advertisement

ATYR vs NTLA

Header iconATYR vs NTLA Comparison
Open Charts ATYR vs NTLABanner chart's image
aTyr Pharma
Price$5.35
Change+$0.21 (+4.09%)
Volume$3.04M
Capitalization474.39M
Intellia Therapeutics
Price$7.58
Change-$0.09 (-1.17%)
Volume$4.33M
Capitalization784.13M
ATYR vs NTLA Comparison Chart
Loading...
ATYR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ATYR vs. NTLA commentary
Jun 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATYR is a Buy and NTLA is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 06, 2025
Stock price -- (ATYR: $5.33 vs. NTLA: $7.57)
Brand notoriety: ATYR and NTLA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATYR: 188% vs. NTLA: 100%
Market capitalization -- ATYR: $474.39M vs. NTLA: $784.13M
ATYR [@Biotechnology] is valued at $474.39M. NTLA’s [@Biotechnology] market capitalization is $784.13M. The market cap for tickers in the [@Biotechnology] industry ranges from $323.27B to $0. The average market capitalization across the [@Biotechnology] industry is $2.31B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATYR’s FA Score shows that 0 FA rating(s) are green whileNTLA’s FA Score has 1 green FA rating(s).

  • ATYR’s FA Score: 0 green, 5 red.
  • NTLA’s FA Score: 1 green, 4 red.
According to our system of comparison, both ATYR and NTLA are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATYR’s TA Score shows that 6 TA indicator(s) are bullish while NTLA’s TA Score has 5 bullish TA indicator(s).

  • ATYR’s TA Score: 6 bullish, 4 bearish.
  • NTLA’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, ATYR is a better buy in the short-term than NTLA.

Price Growth

ATYR (@Biotechnology) experienced а +25.26% price change this week, while NTLA (@Biotechnology) price change was +1.61% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.85%. For the same industry, the average monthly price growth was +10.46%, and the average quarterly price growth was -0.86%.

Reported Earning Dates

ATYR is expected to report earnings on Aug 13, 2025.

NTLA is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+7.85% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NTLA($784M) has a higher market cap than ATYR($474M). ATYR YTD gains are higher at: 47.238 vs. NTLA (-35.077). ATYR has higher annual earnings (EBITDA): -66.37M vs. NTLA (-530.8M). NTLA has more cash in the bank: 504M vs. ATYR (72.1M). ATYR has less debt than NTLA: ATYR (13.3M) vs NTLA (119M). NTLA has higher revenues than ATYR: NTLA (45.6M) vs ATYR (235K).
ATYRNTLAATYR / NTLA
Capitalization474M784M60%
EBITDA-66.37M-530.8M13%
Gain YTD47.238-35.077-135%
P/E RatioN/AN/A-
Revenue235K45.6M1%
Total Cash72.1M504M14%
Total Debt13.3M119M11%
FUNDAMENTALS RATINGS
ATYR vs NTLA: Fundamental Ratings
ATYR
NTLA
OUTLOOK RATING
1..100
193
VALUATION
overvalued / fair valued / undervalued
1..100
83
Overvalued
23
Undervalued
PROFIT vs RISK RATING
1..100
86100
SMR RATING
1..100
9592
PRICE GROWTH RATING
1..100
3590
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5095

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NTLA's Valuation (23) in the Biotechnology industry is somewhat better than the same rating for ATYR (83) in the null industry. This means that NTLA’s stock grew somewhat faster than ATYR’s over the last 12 months.

ATYR's Profit vs Risk Rating (86) in the null industry is in the same range as NTLA (100) in the Biotechnology industry. This means that ATYR’s stock grew similarly to NTLA’s over the last 12 months.

NTLA's SMR Rating (92) in the Biotechnology industry is in the same range as ATYR (95) in the null industry. This means that NTLA’s stock grew similarly to ATYR’s over the last 12 months.

ATYR's Price Growth Rating (35) in the null industry is somewhat better than the same rating for NTLA (90) in the Biotechnology industry. This means that ATYR’s stock grew somewhat faster than NTLA’s over the last 12 months.

ATYR's P/E Growth Rating (100) in the null industry is in the same range as NTLA (100) in the Biotechnology industry. This means that ATYR’s stock grew similarly to NTLA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATYRNTLA
RSI
ODDS (%)
Bearish Trend 2 days ago
88%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
80%
Bullish Trend 1 day ago
84%
Momentum
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 1 day ago
89%
MACD
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 1 day ago
84%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 1 day ago
79%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 1 day ago
90%
Advances
ODDS (%)
Bullish Trend 3 days ago
79%
Bullish Trend 3 days ago
77%
Declines
ODDS (%)
Bearish Trend 22 days ago
84%
Bearish Trend 1 day ago
88%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 1 day ago
82%
Aroon
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 1 day ago
86%
View a ticker or compare two or three
Interact to see
Advertisement
ATYR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JCVIX24.11N/A
N/A
JHancock Classic Value I
ALSAX9.61N/A
N/A
Alger Small Cap Growth A
VCIEX9.11N/A
N/A
VALIC Company I International Eqs Idx
SEEFX20.44N/A
N/A
Saturna Sustainable Equity
TGIWX14.84N/A
N/A
Nuveen Core Equity W

ATYR and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATYR has been loosely correlated with MGTX. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if ATYR jumps, then MGTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATYR
1D Price
Change %
ATYR100%
+3.70%
MGTX - ATYR
44%
Loosely correlated
+0.55%
NTLA - ATYR
39%
Loosely correlated
-1.30%
SLDB - ATYR
38%
Loosely correlated
+10.68%
TCRX - ATYR
37%
Loosely correlated
-6.74%
CRSP - ATYR
37%
Loosely correlated
+1.37%
More

NTLA and

Correlation & Price change

A.I.dvisor indicates that over the last year, NTLA has been closely correlated with VCYT. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if NTLA jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NTLA
1D Price
Change %
NTLA100%
-1.30%
VCYT - NTLA
69%
Closely correlated
-1.17%
CRSP - NTLA
66%
Loosely correlated
+1.37%
BEAM - NTLA
64%
Loosely correlated
-0.87%
RXRX - NTLA
57%
Loosely correlated
-7.13%
ABCL - NTLA
55%
Loosely correlated
-2.27%
More